Catumaxomab

From WikiMD.com - Food, Medicine & Wellness Encyclopedia

(Redirected from Removab)

Catumaxomab[edit | edit source]

Mechanism of action of Catumaxomab

Catumaxomab is a monoclonal antibody that was developed for the treatment of malignant ascites in patients with epithelial cell cancer. It is a bi-specific monoclonal antibody, meaning it is designed to bind to two different types of antigens. Catumaxomab targets the epithelial cell adhesion molecule (EpCAM) on tumor cells and the CD3 antigen on T cells, facilitating a tri-cellular complex that includes tumor cells, T cells, and accessory cells such as macrophages and natural killer cells.

Mechanism of Action[edit | edit source]

Catumaxomab's mechanism of action involves the formation of a tri-cellular complex that enhances the immune system's ability to attack tumor cells. By binding to EpCAM on tumor cells and CD3 on T cells, catumaxomab brings these cells into close proximity, allowing T cells to exert cytotoxic effects on the tumor cells. Additionally, the Fc region of catumaxomab can bind to Fc receptors on accessory cells, further promoting the immune response against the tumor.

Clinical Use[edit | edit source]

Catumaxomab was primarily used for the treatment of malignant ascites, a condition characterized by the accumulation of fluid in the peritoneal cavity due to cancer. This condition is often seen in patients with advanced ovarian cancer, gastric cancer, and other epithelial cancers. The administration of catumaxomab involves intraperitoneal infusion, allowing direct interaction with tumor cells in the peritoneal cavity.

Development and Approval[edit | edit source]

Catumaxomab was developed by the German biotechnology company Trion Pharma in collaboration with Fresenius Biotech. It was approved for use in the European Union in 2009. However, due to various factors, including market conditions and strategic decisions by the developing companies, catumaxomab was withdrawn from the market in 2017.

Structure[edit | edit source]

Structure of Catumaxomab

Catumaxomab is a rat-mouse hybrid monoclonal antibody. It is composed of two different immunoglobulin chains, one derived from a rat and the other from a mouse. This hybrid structure allows it to bind to both human and murine antigens, facilitating its bi-specific action.

Side Effects[edit | edit source]

The administration of catumaxomab can lead to several side effects, primarily due to its immune-stimulating properties. Common side effects include fever, nausea, vomiting, and abdominal pain. These effects are generally manageable with supportive care and premedication.

Related Pages[edit | edit source]

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD